In a mendelian randomisation study, genetic predisposition to higher waist-to-hip ratio adjusted for BMI was associated with an increased risk of type 2 diabetes and coronary heart disease.
The TIMI Risk Score (TRS 2°P) identifies high-risk patients who derive the greatest benefit from the addition of ezetimibe to statin therapy for long-term secondary prevention after ACS.
Canagliflozin had beneficial effects on body weight, BMI, waist circumference, SBP, DBP and HDL-C compared with glimepiride or sitagliptin in T2DM patients with metabolic syndrome.
Real-world data show lower dose NOACs associated with similar risk of thromboembolic events and similar or lower rates of bleeding as compared with warfarin in AF, but mortality risk seems higher with NOACs.
In an analysis from data between 1995 to 2012, changes in risk factors accounted for 57% of the decreased IS incidence and most important contributors were decline in SBP and prevalence of smoking.
This scientific statement is based on literature search and includes experiences with NOAC reversal, in specific situations, temporary NOAC interruption and in periprocedural setting.
Circulating monocytes of FH patients not on statins showed a pro-inflammatory phenotype and intracellular lipid accumulation, which was reversed upon treatment with PCSK9 antibodies.
In HF patients with reduced EF, the continuation or initiation of ACEi/ARB therapy at discharge after admission for acute decompensated HF was associated with lower mortality and readmission rates.
No differences in gait speed decline or mobility limitations were seen in individuals of 75 years and older were seen between those receiving intensive BP-lowering therapy vs. standard therapy.
In a subgroup of PREDIMED study patients it was shown that a Mediterranean diet, especially the one enriched with olive oil, improved biological functions of HDL particles.
In the PARADIGM-HF study, low SBP was associated with higher all-cause death, CV death and heart failure hospitalisation in HF patients, which was lower on sacubitril/valsartan than on enalapril.
CT angiograms in 88 healthy relatives of patients with CAD onset before the age of 40, displayed high plaque burden and more unfavourable plaque features compared to controls.